Anoro Ellipta (umeclidinium/vilanterol) is a brand-name inhaler that’s prescribed for chronic obstructive pulmonary disease (COPD). As with other drugs, Anoro ...
Anoro Ellipta (umeclidinium/vilanterol) is a brand-name drug that’s prescribed for chronic obstructive pulmonary disease (COPD) in adults. Anoro Ellipta comes as an ...
Anoro Ellipta (umeclidinium/vilanterol) is a prescription drug that’s used to treat chronic obstructive pulmonary disease (COPD). Anoro Ellipta’s cost may depend ...
RESEARCH TRIANGLE PARK, N.C. and SOUTH SAN FRANCISCO, Calif., April 28, 2014 /PRNewswire/ -- GlaxoSmithKline plc (lse/nyse:GSK) and Theravance, Inc. THRX +1.96% today announced that Anoro™ Ellipta® ...
Anoro Ellipta (umeclidinium/vilanterol) is a prescription drug that’s used to treat chronic obstructive pulmonary disease (COPD). Anoro Ellipta can interact with ...
ANORO™ ELLIPTA™ approved as first once-daily dual bronchodilator for the treatment of COPD in the US
GlaxoSmithKline plc (LSE/NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the US Food and Drug Administration (FDA) has approved ANORO™ ELLIPTA ...
LONDON, UNITED KINGDOM and SOUTH SAN FRANCISCO, CA--(Marketwired - Oct 17, 2014) - Theravance, Inc. (NASDAQ: THRX) -- Respiratory Medicine has published positive results from a third lung function ...
July 8 (Reuters) - Hong Kong-listed drugmaker Sino Biopharmaceutical said on Wednesday its China unit had secured rights to ...
(HealthDay)—A new inhaled drug to treat a serious lung condition called chronic obstructive pulmonary disease (COPD) has been approved by the U.S. Food and Drug Administration. GlaxoSmithKline's Anoro ...
LONDON — GlaxoSmithKline and Theravance on Monday announced that Anoro Ellipta (umeclidinium and vilanterol inhalation powder), a once-daily that combines two long-acting bronchodilators in a single ...
Anoro(R) (Umeclidinium/Vilanterol) Gains Marketing Authorisation in Europe for the Treatment of COPD
LONDON, UNITED KINGDOM and SOUTH SAN FRANCISCO, CA--(Marketwired - May 8, 2014) - GlaxoSmithKline plc (LSE: GSK) (NYSE: GSK) and Theravance, Inc. (NASDAQ: THRX) today announced that the European ...
MISSISSAUGA, ON, Jan. 9, 2014 /CNW/ - GlaxoSmithKline Inc. and Theravance Inc. today announced that ANORO™ ELLIPTA™ was approved in Canada on December 23, 2013, for the long-term once-daily ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results